- Home
- WBS vs QGEN Comparison
WBS vs QGEN Comparison
Compare WBS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBS
- QGEN
- Stock Information
- Founded
- WBS 1935
- QGEN 1986
- Country
- WBS United States
- QGEN Netherlands
- Employees
- WBS N/A
- QGEN N/A
- Industry
- WBS Major Banks
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WBS Finance
- QGEN Health Care
- Exchange
- WBS Nasdaq
- QGEN Nasdaq
- Market Cap
- WBS 9.1B
- QGEN 9.1B
- IPO Year
- WBS N/A
- QGEN 1996
- Fundamental
- Price
- WBS $51.49
- QGEN $45.14
- Analyst Decision
- WBS Strong Buy
- QGEN Buy
- Analyst Count
- WBS 13
- QGEN 8
- Target Price
- WBS $63.38
- QGEN $50.53
- AVG Volume (30 Days)
- WBS 1.1M
- QGEN 1.5M
- Earning Date
- WBS 06-26-2025
- QGEN 05-07-2025
- Dividend Yield
- WBS 3.11%
- QGEN 2.92%
- EPS Growth
- WBS N/A
- QGEN N/A
- EPS
- WBS 4.44
- QGEN 0.42
- Revenue
- WBS $2,372,492,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- WBS $10.11
- QGEN $6.11
- Revenue Next Year
- WBS $5.18
- QGEN $6.10
- P/E Ratio
- WBS $11.60
- QGEN $107.32
- Revenue Growth
- WBS N/A
- QGEN 3.31
- 52 Week Low
- WBS $39.34
- QGEN $37.63
- 52 Week High
- WBS $63.99
- QGEN $47.93
- Technical
- Relative Strength Index (RSI)
- WBS 54.03
- QGEN 66.03
- Support Level
- WBS $49.81
- QGEN $41.77
- Resistance Level
- WBS $52.69
- QGEN $43.01
- Average True Range (ATR)
- WBS 1.15
- QGEN 0.70
- MACD
- WBS -0.11
- QGEN 0.24
- Stochastic Oscillator
- WBS 43.19
- QGEN 93.82
About WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).